Compare Eos Energy Enterprises Inc (EOSE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Merck & Co., Inc. — how do they compare? Eos Energy Enterprises Inc trades at $4.27 (market cap $1.54B), while Merck & Co., Inc. trades at $133.41 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 208.9× Eos Energy Enterprises Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | MRK | |
|---|---|---|
Market Cap | $1.54B | $321.77B |
Sector | Energy | Health |
52-Week High | $19.19 | $131.84 |
52-Week Low | $3.14 | $77.60 |
Enterprise Value | $1.88B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.24, up 4.69% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 loss per share. Financials reveal significant challenges with negative gross margins of -84.75% and net income margin of -246.76% for 2026, though revenue growth from $114M to $214M year-over-year shows scaling progress.
While analyst consensus targets $7.75 (83% upside), the stock faces substantial fundamental risks including negative profitability, shareholder litigation investigation, and high debt-to-asset ratio of 91.87%. The company's energy storage technology and growing backlog provide potential, but execution risks and cash burn require careful monitoring for investors considering this speculative growth play.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
